ライフサイエンスコーパス: alprazolam

1 after treatment with either placebo or 1 mg alprazolam.

2 ls associated with the anxiolytic effects of alprazolam.

3 may be related to the anxiolytic effects of alprazolam.

4 re increased following prior euglycemia with alprazolam.

5 both before and during their treatment with alprazolam.

6 ine, atenolol, sulfamethazine, diazepam, and alprazolam.

7 were augmented with D-cycloserine (50 mg) or alprazolam (0.25 mg) in a double-blind, placebo-controll

8 pe mice after saline, diazepam (1mg/kg), and alprazolam (0.3mg/kg) injections.

9 1), 450 mg/d (n = 90), or 600 mg/d (n = 89); alprazolam, 1.5 mg/d (n = 93); or placebo (n = 91).

10 ), and 600 mg (-11.8 +/- 0.8, P = .002), and alprazolam (-10.9 +/- 0.8, P = .02).

11 tested the effects of a single oral dose of alprazolam (a classical benzodiazepine acting as alloste

12 In contrast to placebo, alprazolam abolished the activation of the rACC after ch

13 Alprazolam activation of GABA(A) pathways during day 1 h

14 during CNB (relaxation group), and 0.5-mg of alprazolam administered orally 15 minutes before CNB (me

15 After 14 d of alprazolam administration (90 mg x kg(-1) x d(-1)), spon

16 Both acute and chronic alprazolam administration was found to decrease CRF conc

17 We investigated whether the benzodiazepine alprazolam affects activity in distinct brain regions wi

18 razolam increased punished responding, while alprazolam alone had no effect on either non-punished re

19 Alprazolam and diazepam increased the amplitude of the n

20 Alprazolam and placebo differed significantly on the Cli

21 hters of alcoholics) after challenge does of alprazolam and placebo in comparison with responses in w

22 enobiotics such as methamphetamine, codeine, alprazolam, and morphine, revealing that NIMS can be use

23 , the median environmental emission rates of alprazolam (APZ) and carbamazepine (CBZ) through domesti

24 y suggest that the mood-enhancing effects of alprazolam are greater in daughters of alcoholics than i

25 Alprazolam blocked or reversed each of these effects.

26 GABA(A) receptor subunit expression and that alprazolam can block or reverse those effects.

27 d (GABA) A receptors with the benzodiazepine alprazolam can blunt physiologic responses during next-d

28 hese results demonstrate that punishment and alprazolam can produce reciprocal changes in the mRNA le

29 ude that activation of GABA A receptors with alprazolam can result in widespread neuroendocrine, auto

30 alcoholics and 11 comparison subjects after alprazolam challenge.

31 on vs time (P<.001) and a 2-fold increase in alprazolam clearance (P<.001) were observed following St

32 ity exposure augmented with D-cycloserine or alprazolam, compared with placebo, in reducing posttraum

33 Furthermore, chronic alprazolam decreased basal activity of the hypothalamic-

34 Participants were also administered alprazolam (double-blinded, placebo-controlled crossover

35 y 2 exercise studies, GABA A activation with alprazolam during day 1 euglycemia resulted in significa

36 uring day 2 studies, GABA(A) activation with alprazolam during day 1 euglycemia resulted in significa

37 GABA(A) activation with alprazolam during prior hypoglycemia caused further sign

38 Alprazolam elimination half-life was shortened from a me

39 or hypoglycemic clamps with or without 1 mg alprazolam given 30 min before a clamp.

40 l/L hypoglycemic clamps with or without 1 mg alprazolam given 30 min before each clamp.

41 d end point, the 3 pregabalin groups and the alprazolam group had significantly (P<.01) improved HAM-

42 TSD diagnosis at 3 months posttreatment; the alprazolam group showed a higher rate of PTSD (82.8%) th

43 nly from the placebo group but also from the alprazolam group.

44 n (week 1, P = .06; week 4, P = .32) and the alprazolam groups (week 1, P = .21; week 4, P = .15).

45 Alprazolam had no effect on non-suppressed licking, [(3)

46 In secondary analyses, alprazolam impaired recovery and D-cycloserine enhanced

47 -GSK), 400 mg GSK561679 (high-GSK), and 1 mg alprazolam in a crossover design.

48 s withdrawal from the triazolobenzodiazepine alprazolam in dependent rats and to characterize the tim

49 All of these effects were reversed when alprazolam increased punished responding, while alprazol

50 rison subjects despite having similar plasma alprazolam levels.

51 e also seen in vehicle-treated cage-mates of Alprazolam/Modafinil-treated mice, suggesting that behav

52 ration of the triazolobenzodiazepine agonist alprazolam on CRF peptide concentrations, receptor-bindi

53 GABA(A) activation using the benzodiazepine alprazolam on the neuroendocrine and autonomic nervous s

54 rmone responses were similarly reduced after alprazolam or day 1 hypoglycemia compared with euglycemi

55 c hypoglycemia (2.9 mmol/l) with either 1 mg alprazolam or placebo administered 30 min before the sta

56 ortisol and startle reactivity more than did alprazolam or placebo, findings that are consistent with

57 period taking either diazepam, lorazepam, or alprazolam, patients were treated for 4 weeks with imipr

58 ctivity of CYP 3A4 as measured by changes in alprazolam pharmacokinetics.

59 old decrease in the area under the curve for alprazolam plasma concentration vs time (P<.001) and a 2

60 ere unaffected by punishment were altered by alprazolam plus punishment.

61 Pregabalin and alprazolam produced a significantly greater reduction in

62 ACC correlated with the anxiolytic effect of alprazolam (r(p) = .52; p = .04).

63 ory gamma-aminobutyric acidergic action with alprazolam reduced anxiety and restored feedback modulat

64 hat chronic administration of the anxiolytic alprazolam reduced indices of CRF and CRF1 receptor func

65 Consistent with previous findings, alprazolam reduced startle potentiation during unpredict

66 Prior hypoglycemia with alprazolam resulted in further reduction of glucagon and

67 , enhancement of gamma2-GABAAR function with alprazolam reversed the stress-induced increase in the f

68 (relative risk or RR = 1.69); loratadine and alprazolam (RR = 1.86); loratadine and duloxetine (RR =

69 easant mood responses after a single dose of alprazolam than did the comparison subjects despite havi

70 gs to manage sleep/wake cycles in R6/2 mice, Alprazolam (to put them to sleep) and Modafinil (to wake

71 drugs (30 mg of dextromethorphan and 2 mg of alprazolam) to establish baseline CYP 3A4 and CYP 2D6 ac

72 ocortin I-CRF2A function, altered by chronic alprazolam treatment as previously described, returned t

73 te cortex (rACC), which was attenuated after alprazolam treatment.

74 e the full allosteric modulators (FAM), like alprazolam, triazolam, and diazepam, PAMs are virtually

75 izes terfenadine, astemizole, carbamazepine, alprazolam, triazolam, and other benzodiazepines.

76 or associated with the anxiolytic effects of alprazolam were measured in 20 brain regions using in si

77 at GABA A activation with the benzodiazepine alprazolam would blunt counterregulatory responses durin